Evidence map›Paper›PMID 28892262›Full record

ArticleAdvanced healthcare materials2018

Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.

Mo-Yuan Shen, Jie-Fu Chen, Chun-Hao Luo, Sangjun Lee, Cheng-Hsuan Li, Yung-Ling Yang, Yu-Han Tsai, Bo-Cheng Ho, Li-Rong Bao, Tien-Jung Lee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mo-Yuan ShenSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.
Jie-Fu ChenSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Chun-Hao LuoSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.
Sangjun LeeDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Cheng-Hsuan LiSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.
Yung-Ling YangSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.
Yu-Han TsaiSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.
Bo-Cheng HoDepartment of Material Engineering, Ming Chi University of Technology, 84 Gungjuan Rd., Taishan Dist., New Taipei City, 24301, Taiwan.
Li-Rong BaoDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Tien-Jung LeeDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Yu Jen JanDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Ya-Zhen ZhuDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Shirley ChengSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Felix Y FengDepartments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, San Francisco, CA, 94158, USA.
Peilin ChenResearch Center for Applied Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Shuang HouLiver Transplantation and Hepatobiliary Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Vatche AgopianLiver Transplantation and Hepatobiliary Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Yu-Sheng HsiaoDepartment of Material Engineering, Ming Chi University of Technology, 84 Gungjuan Rd., Taishan Dist., New Taipei City, 24301, Taiwan.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Edwin M PosadasSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Hsiao-Hua YuSmart Organic Material Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Rd., Nankang, Taipei, 11529, Taiwan.

Funding

A blood test to identify prostate cancer patients at risk for visceral metastasisR01CA218356 · NCI · CEDARS-SINAI MEDICAL CENTER · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2017 to 2021
$3.0M
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
Molecular and Functional Analysis of Single Circulating Melanoma CellsR33CA174562 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2015
$987k
Advanced Development of An Integrated CTC Enrichment TechnologyR33CA157396 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2011 to 2013
$672k
3D-Nanostrcutured Substrates for Detection of Circulating Tumor CellsR21CA151159 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2010 to 2011
$362k
NCI NIH HHS R01 CA218356NCI NIH HHS R21 CA151159NCI NIH HHS R33 CA157396NCI NIH HHS R33 CA174562NCI NIH HHS U01 CA198900
6 · The paper itself

Abstract

A glycan-stimulated and poly(3,4-ethylene-dioxythiophene)s (PEDOT)-based nanomaterial platform is fabricated to purify circulating tumor cells (CTCs) from blood samples of prostate cancer (PCa) patients. This new platform, phenylboronic acid (PBA)-grafted PEDOT NanoVelcro, combines the 3D PEDOT nanosubstrate, which greatly enhances CTC capturing efficiency, with a poly(EDOT-PBA-co-EDOT-EG3) interfacial layer, which not only provides high specificity for CTC capture upon antibody conjugation but also enables competitive binding of sorbitol to gently release the captured cells. CTCs purified by this PEDOT NanoVelcro chip provide well-preserved RNA transcripts for the analysis of the expression level of several PCa-specific RNA biomarkers, which may provide clinical insights into the disease.

Indexed as

BiomarkersBridged Bicyclo Compounds, HeterocyclicCell Line, TumorHumansMaleNanostructuresNeoplastic Cells, CirculatingPolymersProstatic NeoplasmsRNABiomarkersBridged Bicyclo Compounds, Heterocyclicpoly(3,4-ethylene dioxythiophene)PolymersRNAcirculating tumor cellspoly(3,4-ethylene-dioxythiophene)sprostate cancerresponsive materialsRNA biomarkers

Identifiers

PMID28892262
PMCPMC5803304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.